Impact of new functional imaging modalities on radiation therapy regimen for glioblastoma;Apport des nouvelles techniques d'imagerie à la planification radiothérapique des patients porteurs de glioblastome polymorphe

Bulletin du Cancer

Volumn 92, Issue 4, 2005, Pages 333-342

  Dhermain, Frédéric ^a   Ducreux, Denis ^b   Bidault, François ^a   Bruna, Antoine ^a   Parker, Fabrice ^b   Roujeau, Thomas ^c   Beaudre, Anne ^a   Armand, Jean Pierre ^a   Haie Meder, Christine ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b BICÊTRE HOSPITAL   (France)

^c Service de Neurochirurgie   (France)

Author keywords

Functional imaging; Glioblastoma multiforme; Radiotherapy; Treatment planning

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 123; METHIONINE; METIROSINE; METIROSINE I 123; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER INFILTRATION; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLIOBLASTOMA; HUMAN; MICROSCOPY; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPTICAL RESOLUTION; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT FAILURE; TREATMENT PLANNING; TUMOR RECURRENCE; BRAIN TUMOR; COMPUTER ASSISTED RADIOTHERAPY; DIAGNOSTIC IMAGING; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REVIEW;

BRAIN NEOPLASMS; DIAGNOSTIC IMAGING; FLUORODEOXYGLUCOSE F18; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 18344376234     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Frappaz D, et le groupe de travail SOR. Standards, Options et Recommandations 2002 pout la prise en charge des patients atteints de gliomes intracrâniens de l'adulte (rapport abrégé). Bull Cancer 2003; 90: 873-86.
2. Caspar LE, Fisher BJ, MacDonald DR. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 1992; 24: 55-7.
3. Mirimanoff R, Mason W, Kortmann R, van den Bent M, Fisher B, Taphoorn M, et al. Radiotherapy (RT) and concomitant and adjuvant temozolomide (TMZ) versus radiotherapy alone for newly diagnosed glioblastoma (GBM): overall results and recursive partitioning analysis (RPA) of a phase III randomised trial of the EORTC brain tumor and radiotherapy groups and the NCIC clinical trial group. Int J Radiat Oncol Biol Phys 2004; 60: S163-4 [Abstr. 55].
4. Halperin EC, Bentel G, Heinz ER, Buger PC. Radiation therapy treatment planning in supratentorial glioblastoma multiforme: an analysis based on post mortem topographic anatomy with CT correlations. Int J Radiat Oncol Biol Phys 1989; 17: 1347-50.
5. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980; 30: 907-11.
6. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 1987; 66: 865-74.
7. Nataf F. La neurochirurgie «conservatrice». Bull Cancer 2002; 89: 1053-60.
8. Selker RG, Shapiro WR, Burger P, Blackwood MS, Deursch M, Arena VC, et al. The Brain Tumor Cooperative Group NIH trial. 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, intersticial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 2002; 51: 343-55.
9. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004; 60: 853-60.
10. www.rtog.org/members/protocols/98-03/main.html
11. Werner-Wasik M, Seiferheld W, Michalski J, Gilbert M, Purdy J, Simpson J, et al. Phase I/II conformal three-dimensional radiation therapy dose escalation study in patients with supratentorial glioblastoma multiforme: report of the Radiation Therapy Oncology Group 98-03 Protocol. Int J Radiat Oncol Biol Phys 2004; 60: S163-4 [Abstr. 58].
12. www.rtog.org/members/protocols/brOO23/main.html
13. Nakagawa K, Aoki Y, Fujimaki T, Tago M, Terahara A, Karasawa K, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998; 40: 1141-9.
14. Chan JL, Lee SW, Fraas BA, Normolle DP, Greenberg HS, Junck LR, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002; 20: 1635-42.
15. Levin VA, Yung WK, Bruner J, Kyritsis A, Leeds N, Gleason MJ, et al. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 2002; 53: 58-66.
16. Jansen EP, Dewit LG, van Herk M, Bartelink H. Target volumes in radiotherapy for high-grade malignant glioma of the brain. Radiother Oncol 2000; 56: 151-6.
17. Kantor G, Loiseau H, Vital A, Mazeron JJ. Volume tumoral macroscopique (GTV) et volume-cible anatomoclinique (CTV) des tumeurs gliales de l'adulte. Cancer Radiother 2001; 5: 571-80.
18. Grosu AL, Weber W, Feldmann HJ, Wuttke B, Bartenstein P, Gross MW, et al. First experience wich I-123-alpha-methyl-tyrosine SPECT in the 3-D treatment planning of brain gliomas. Int J Radiat Oncol Biol Phys 2000; 47: 517-26.
19. Grosu AL, Weber W, Feldmann HJ, Dick S, Dzewas B, Nieder C, et al. Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. Int J Radiat Oncol Biol Phys 2002; 54: 842-54.
20. Provenzale JM, McGraw P, Mhatre P, Guo AC, Delong D. Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-censor MR imaging. Radiology 2004; 232: 451-60.
21. Herminghaus S, Dieks T, Pilatus U. Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data. J Neurosurg 2003; 98: 74-81.
22. Shaw EG, Seiferheld W, Cairncross JG, Jenkins R, Scheirhauer N, Brachman D, et al. Radiation therapy alone versus intensive procarbazine-CCNU-vincristine (I-PCV) chemotherapy followed by radiation therapy for anaplastic oligodendroglioma (AO) and mixed oligo-astrocycoma (MOA): results of Radiation Therapy Oncology Group (RTOG) Intergroup Protocol 94-02. Int J Radiat Oncol Biol Phys 2004; 60: S163 [Abstr. 57].
23. In: EORTC 26981/22981 Phase III trial: RT and concomitant and adjuvant TMZ for GBM, final version. March 2000.
24. Roux FE, Ibarrola D, Tremoulet M, Lazorrhes Y, Henry P, Sol JC, et al. Methodological and technical issues for integrating functional magnetic resonance imaging data in a neuronavigational system. Neurosurgery 2001; 49: 1145-57.
25. Keles EG, Berger MS. Advances in neurosurgical technique in the current management of brain tumors. Semin Oncol 2004; 31: 659-65.
26. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001; 219: 316-33.
27. Coleman CN. Linking radiation oncology and imaging through molecular biology (or now that therapy and diagnosis have separated, it's time to get together again). Radiology 2003; 228: 29-35.
28. www.asco.org Prados M. Future directions in clinical research in Neuro-Oncology. Education Program ASCO 2004.
29. Lawrence TS. In: Beyond the technical limits of radiation therapy Presidential Address. 46th Annual ASTRO meeting. Atlanta. 2004.
30. Hamilton RJ, Sweeney PJ, Pelizzari CA, Yetkin FZ, Holman BL, Garada B, et al. Functional imaging in treatment planning of brain lesions. Int J Radiat Oncol Biol Phys 1997; 37: 181-8.
31. Fitzek M, Pardo FS, Aronen H, Busierre M, Lev M, Fischman A, et al. Use of the functional imaging modalities, fMRI rCBV and PET FDG, alters radiation therapy 3-D treatment planning in patients with malignant gliomas. Int J Radiat Oncol Biol Phys 1995: S151 [Abstr. 20].
32. Narayana A, Chang J, Thakur S, Huang W, Kowalski A, Perera G, et al. Use of MR Spectroscopy and functional imaging in the treatment planning of gliomas. Proc ASTRO 2004, Atlanta. Int J Radiat Oncol Biol Phys 2004: S222; [Abstr. 153].
33. Chang J, Thakur S, Perera G, Kowalski A, Huang W, Karimi S, et al. Image-fusion of MR Spectroscopic images for treatment planning of gliomas. Proc ASTRO 2004, Atlanta. Int J Radiat Oncol Biol Phys 2004: S223 [Abstr. 154].
34. Tsien C, Gomez Hassan D, Chenevert T, Ten Haken R, Lawrence T, Junck L, et al. Quantitative measurement of regional signal intensity changes of high-grade gliomas following radiotherapy using T1-Weighted contrast enhanced MRI imaging. Proc ASTRO 2004, Atlanta. Int J Radiat Oncol Biol Phys 2004: S165 [Abstr. 61].
35. Grosu AL, Lachner R, Wiedenmann N, Stärck S, Thamm R, Kneschaurek P, et al. Validation of a method for automatic image fusion (Brainlab system) of CT data and HC-Methionine-PET data for sterotactic radiotherapy using a linac: first clinical experience. Int J Radiat Oncol Biol Phys 2003; 56: 1450-63.
36. Pirzkall A, McKnight TR, Graves EE, Carol MP, Sneed PK, Wara WW, et al. MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys 2001; 50: 915-28.
37. Pirzkall A, Li X, Oh J, Chang S, Berger M, Larson D, et al. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys 2004; 59: 126-37.
38. Gross MW, Weber WA, Feldmann HJ, Bartenstein P, Schwaiger M, Molls M. The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys 1998; 41: 989-95.
39. Chuang C, Chan A, Larson D, Nelson S, Pirzkall A. Prognostic value of pre-Gamma Knife Spectroscopic imaging for treatment strategy and clinical outcome. Proc ASTRO 2004, Atlanta. Int J Radiat Oncol Biol Phys 2004: S166 [Abstr. 62].
40. McKnight TR. Proton magnetic resonance spectroscopic evaluation of brain tumor metabolism. Semin Oncol 2004; 311: 605-17.
41. McKnight TR, Von dem Bussche MH, Vigneron DB, Lu Y, Berger MS, McDermott MW, et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002; 97: 794-802.
42. Cha S, Knopp EA, Johnson G, Wetzel SG, Litt AW, Zagzag D. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echoplanar perfusion MR Imaging. Radiology 2002; 223: 11-29.
43. Lu S, Ahn D, Johnson G, Law M, Zagzag D, Grossman RI. Diffusion-tensor MR imaging of intracranial neoplasia and associated peritumoral edema: introduction of the tumor infiltration index. Radiology 2004; 232: 221-8.
44. Provenzale JM, Wang GR, Brenner T, Petrella JR, Sorensen G. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. Am J Roentgenol 2002; 178: 711-6.
45. Standards, Options et Recommandations 2002 pour l'utilisation de la tomographie par émission de positons au [18F]-FDG (TEP-FDG) en cancérologie (rapport intégral). Bull Cancer 2003; 90 (numéto spécial): 1S-109S.
46. Touboul E, Deniaud-Alexandre A, Moureau-Zabotto L, Lerouge D. Tomographie par émission de positons et fusion d'images de simulation virtuelle par tomodensitométrie: impact sur la planification de la radiothé rapie. Cancer Radiother 2004; 8: S29-35.
47. Weltens C, Menten J, Feron M, Bellon E, Demaerel P, Maes F, et al. Inter-observer variations in gross tumor volume delineation of brain tumors on computed tomography and impact of magnetic resonance imaging. Radiother Oncol 2001; 60: 49-59.
48. Mazzara GP, Velthuizen RP, Pearlman JL, Greenberg HM, Wagner H. Brain tumor target volume determination for radiation treatment planning through automated MRI segmentation. Int J Radiat Oncol Biol Phys 2004; 59: 300-12.
49. Chakravarti A, Seiferheld W, Robins H, Guha A, Brachman D, Curran W, et al. An update of phase I data from RTOG 0211: a phase I/II clinical study og gefitinib + radiation for newly-diagnosed glioblastoma (GBM) patients. Proc ASCO, New Orleans, LA. J Clin Oncol 2004; 23: S124 [Abstr. 1571).
50. Geyer JR, Boyett J, Douglas J, Phillips P, Young-Poussaint T, Packer R, et al. Phase I trial of ZD1839 (Iressa) and radiation in pediatric patients newly diagnosed with brain stem tumors or incompletely resected supratentorial malignant gliomas. Int J Radiat Oncol Biol Phys 2004; 60: S251 [Abstr. 198].
51. Haas-Kogan DA, Prados MD, Jelluma N, Arvold ND, Lamborn KR, Kapadia A, et al. Expression levels of EGFR in malignant gliomas are associated with response to treatment with the EGFR inhibitor OSI-774. Int J Radiat Oncol Biol Phys 2004; 60: S148 (Abstr. 32].
52. Bonner JA, Giralt J, Harati PM, Cohen R, Jones C, Sur K, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. ASCO Annual Meeting Proceedings. J Clin Oncol 2004; 22: 14S [Abstr. 5507].